Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Receivables (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Receivables data on record, last reported at $2.0 million in Q4 2025.

  • For Q4 2025, Receivables rose 187.86% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, up 187.86%, while the annual FY2025 figure was $2.0 million, 187.86% up from the prior year.
  • Receivables reached $2.0 million in Q4 2025 per CLDX's latest filing, up from $90000.0 in the prior quarter.
  • Across five years, Receivables topped out at $2.7 million in Q1 2024 and bottomed at $90000.0 in Q2 2025.
  • Average Receivables over 5 years is $844850.0, with a median of $421500.0 recorded in 2021.
  • Peak YoY movement for Receivables: soared 1200.0% in 2024, then tumbled 94.13% in 2025.
  • A 5-year view of Receivables shows it stood at $172000.0 in 2021, then surged by 101.74% to $347000.0 in 2022, then surged by 657.35% to $2.6 million in 2023, then tumbled by 73.36% to $700000.0 in 2024, then soared by 187.86% to $2.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $2.0 million in Q4 2025, $90000.0 in Q3 2025, and $90000.0 in Q2 2025.